KRYS Krystal Biotech Inc
Price (delayed)
$181
Market cap
$5.21B
P/E Ratio
58.01
Dividend/share
N/A
EPS
$3.12
Enterprise value
$4.88B
Krystal Biotech, Inc. is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases.
Highlights
The EPS has soared by 70% from the previous quarter
The net income has soared by 70% from the previous quarter
The company's quick ratio has shrunk by 60% YoY and by 10% QoQ
Key stats
What are the main financial stats of KRYS
Market
Valuations
Earnings
Shares outstanding
28.81M
Market cap
$5.21B
Enterprise value
$4.88B
Price to earnings (P/E)
58.01
Price to book (P/B)
5.5
Price to sales (P/S)
17.81
EV/EBIT
51.14
EV/EBITDA
47.77
EV/Sales
16.79
Revenue
$290.52M
Gross profit
$270.45M
Operating income
$65.7M
Net income
$89.16M
EBIT
$95.36M
EBITDA
$102.07M
Free cash flow
$119.18M
Per share
Balance sheet
Liquidity
EPS
$3.12
EPS diluted
$3
Free cash flow per share
$4.17
Book value per share
$32.91
Revenue per share
$10.16
TBVPS
$36.93
Total assets
$1.06B
Total liabilities
$109.46M
Debt
$7.26M
Equity
$946.38M
Working capital
$640.05M
Debt to equity
0.01
Current ratio
7.28
Quick ratio
6.89
Net debt/EBITDA
-3.31
Margins
Efficiency
Dividend
EBITDA margin
35.1%
Gross margin
93.1%
Net margin
30.7%
Operating margin
22.6%
Return on assets
9.4%
Return on equity
10.3%
Return on invested capital
18.1%
Return on capital employed
10%
Return on sales
32.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KRYS stock price
How has the Krystal Biotech stock price performed over time
Intraday
3.68%
1 week
-3.26%
1 month
0.98%
1 year
2.31%
YTD
15.54%
QTD
0.39%
Financial performance
How have Krystal Biotech's revenue and profit performed over time
Revenue
$290.52M
Gross profit
$270.45M
Operating income
$65.7M
Net income
$89.16M
Gross margin
93.1%
Net margin
30.7%
The operating income has soared by 160% YoY and by 139% from the previous quarter
The operating margin has soared by 110% YoY and by 98% from the previous quarter
The net income has soared by 70% from the previous quarter
The net margin has grown by 42% YoY and by 41% from the previous quarter
Growth
What is Krystal Biotech's growth rate over time
Valuation
What is Krystal Biotech stock price valuation
P/E
58.01
P/B
5.5
P/S
17.81
EV/EBIT
51.14
EV/EBITDA
47.77
EV/Sales
16.79
The EPS has soared by 70% from the previous quarter
KRYS's price to earnings (P/E) is 22% lower than its last 4 quarters average of 71.9
KRYS's P/B is 33% above its 5-year quarterly average of 4.0 but 8% below its last 4 quarters average of 5.8
Krystal Biotech's equity has increased by 22% YoY and by 7% QoQ
The P/S is 43% below the last 4 quarters average of 30.3
The revenue has grown by 20% since the previous quarter
Efficiency
How efficient is Krystal Biotech business performance
The ROE has soared by 63% from the previous quarter
Krystal Biotech's ROA has soared by 59% from the previous quarter
Krystal Biotech's return on invested capital has surged by 52% QoQ
The ROS has grown by 38% from the previous quarter and by 29% YoY
Dividends
What is KRYS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KRYS.
Financial health
How did Krystal Biotech financials performed over time
The total liabilities has soared by 176% YoY and by 13% from the previous quarter
The company's quick ratio has shrunk by 60% YoY and by 10% QoQ
The debt is 99% less than the equity
Krystal Biotech's equity has increased by 22% YoY and by 7% QoQ
The debt has contracted by 10% YoY and by 2.9% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.